CNTB · Connect Biopharma Holdings Ltd

NasdaqHealthcareBiotechnology

Connect Biopharma Holdings Ltd Is A Clinical-Stage Biopharmaceutical Company Dedicated To Transforming Care For Asthma And Chronic Obstructive Pulmonary Disease (Copd). The Company Is Advancing Rademikibart, A Next-Generation Antibody Designed To Target Interleukin-4-Receptor Alpha. It Is Currently Conducting Clinical Studies Of Rademikibart For The Treatment Of Acute Exacerbations Of Asthma And Copd. The Company Operates In One Operating Segment: Treatment Of Respiratory Diseases.

HealthcareNasdaqUSMid Float

$2.06

+102.4% latest move

Price & move as of the most recent catalyst (Sep 30) — not a live quote.

FLOAT

20.0M

FREE FLOAT %

32%

SHARES O/S

63.0M

MARKET CAP

$57.0M

EXCHANGE

Nasdaq

COUNTRY

CNTB Catalyst History

Regulatory and ClinicalPositive Topline ResultsSep 30, 2026 · 7:03am ET

CNTBConnect Biopharma Holdings Ltd

Be early on the next CNTB spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →

CNTB · Connect Biopharma Holdings Ltd

CNTB Catalyst History

Connect Biopharma Announces Positive Preliminary Topline Data from Global Phase 2 Study of Rademikibart

Connect Biopharma Announces Positive Preliminary Topline Data from Global Phase 2 Study of Rademikibart